IDYA
Price
$36.04
Change
-$0.99 (-2.67%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
3.25B
75 days until earnings call
Intraday BUY SELL Signals
REGN
Price
$741.92
Change
-$12.22 (-1.62%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
79.26B
15 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs REGN

Header iconIDYA vs REGN Comparison
Open Charts IDYA vs REGNBanner chart's image
IDEAYA Biosciences
Price$36.04
Change-$0.99 (-2.67%)
Volume$8.41K
Capitalization3.25B
Regeneron Pharmaceuticals
Price$741.92
Change-$12.22 (-1.62%)
Volume$16.01K
Capitalization79.26B
IDYA vs REGN Comparison Chart in %
IDYA
Daily Signal:
Gain/Loss:
REGN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IDYA vs. REGN commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and REGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (IDYA: $37.03 vs. REGN: $754.14)
Brand notoriety: IDYA: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 164% vs. REGN: 68%
Market capitalization -- IDYA: $3.25B vs. REGN: $79.26B
IDYA [@Biotechnology] is valued at $3.25B. REGN’s [@Biotechnology] market capitalization is $79.26B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 2 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 2 green, 3 red.
According to our system of comparison, REGN is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 3 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 4 bearish.
  • REGN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both IDYA and REGN are a good buy in the short-term.

Price Growth

IDYA (@Biotechnology) experienced а -2.19% price change this week, while REGN (@Biotechnology) price change was -7.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.44%. For the same industry, the average monthly price growth was +2.31%, and the average quarterly price growth was +42.34%.

Reported Earning Dates

IDYA is expected to report earnings on Mar 31, 2026.

REGN is expected to report earnings on Jan 30, 2026.

Industries' Descriptions

@Biotechnology (-0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($79.3B) has a higher market cap than IDYA($3.25B). IDYA YTD gains are higher at: 7.116 vs. REGN (-2.297). REGN has higher annual earnings (EBITDA): 5.71B vs. IDYA (-204.84M). REGN has more cash in the bank: 8.44B vs. IDYA (787M). IDYA has less debt than REGN: IDYA (27.2M) vs REGN (2.71B). REGN has higher revenues than IDYA: REGN (14.2B) vs IDYA (215M).
IDYAREGNIDYA / REGN
Capitalization3.25B79.3B4%
EBITDA-204.84M5.71B-4%
Gain YTD7.116-2.297-310%
P/E RatioN/A18.08-
Revenue215M14.2B2%
Total Cash787M8.44B9%
Total Debt27.2M2.71B1%
FUNDAMENTALS RATINGS
IDYA vs REGN: Fundamental Ratings
IDYA
REGN
OUTLOOK RATING
1..100
2165
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
3
Undervalued
PROFIT vs RISK RATING
1..100
5773
SMR RATING
1..100
9454
PRICE GROWTH RATING
1..100
4014
P/E GROWTH RATING
1..100
10045
SEASONALITY SCORE
1..100
5040

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is in the same range as IDYA (27) in the null industry. This means that REGN’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (57) in the null industry is in the same range as REGN (73) in the Biotechnology industry. This means that IDYA’s stock grew similarly to REGN’s over the last 12 months.

REGN's SMR Rating (54) in the Biotechnology industry is somewhat better than the same rating for IDYA (94) in the null industry. This means that REGN’s stock grew somewhat faster than IDYA’s over the last 12 months.

REGN's Price Growth Rating (14) in the Biotechnology industry is in the same range as IDYA (40) in the null industry. This means that REGN’s stock grew similarly to IDYA’s over the last 12 months.

REGN's P/E Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for IDYA (100) in the null industry. This means that REGN’s stock grew somewhat faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAREGN
RSI
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
39%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
69%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
48%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
43%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
54%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
68%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 9 days ago
65%
Declines
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 2 days ago
51%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
49%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signal:
Gain/Loss:
REGN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SFGIX15.620.08
+0.51%
Seafarer Overseas Gr and Income Investor
OCIEX16.130.05
+0.31%
Optimum International C
TRMSX22.88-0.03
-0.13%
T. Rowe Price Mid-Cap Index I
PFGEX28.17-0.28
-0.98%
Parnassus Growth Equity Investor
TWUIX101.21-1.22
-1.19%
American Century Ultra® I

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+5.53%
NUVL - IDYA
59%
Loosely correlated
+6.59%
XNCR - IDYA
58%
Loosely correlated
+3.66%
XENE - IDYA
57%
Loosely correlated
+3.02%
DYN - IDYA
55%
Loosely correlated
+2.41%
VIR - IDYA
55%
Loosely correlated
+8.08%
More

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with BMRN. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then BMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-0.63%
BMRN - REGN
40%
Loosely correlated
+1.59%
SMMT - REGN
38%
Loosely correlated
+5.00%
INCY - REGN
38%
Loosely correlated
+2.44%
ARQT - REGN
37%
Loosely correlated
+2.61%
IDYA - REGN
37%
Loosely correlated
+5.53%
More